Replies to post #251358 on Biotech Values

[DewDiligence]

GRTS—(-48%)—adds insult to injury with a warrant-laden financing immediately following yesterday’s clinical failure (#msg-174154327):

https://finance.yahoo.com/news/gritstone-bio-announces-pricing-32-030000199.html

This is something you don't see very often.